{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:54:36Z","timestamp":1789512876064,"version":"build-2803163510"},"reference-count":160,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,4,15]],"date-time":"2015-04-15T00:00:00Z","timestamp":1429056000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Sex Health Rep"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s11930-015-0045-y","type":"journal-article","created":{"date-parts":[[2015,4,14]],"date-time":"2015-04-14T05:36:47Z","timestamp":1428989807000},"page":"117-131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Peyronie\u2019s Disease: A Review of Etiology, Diagnosis, and Management"],"prefix":"10.1007","volume":"7","author":[{"given":"Aylin N.","family":"Bilgutay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander W.","family":"Pastuszak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,15]]},"reference":[{"issue":"3","key":"45_CR1","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.eururo.2005.10.026","volume":"49","author":"AI El-Sakka","year":"2006","unstructured":"El-Sakka AI. Prevalence of Peyronie\u2019s disease among patients with erectile dysfunction. Eur Urol. 2006;49(3):564\u20139.","journal-title":"Eur Urol"},{"issue":"5","key":"45_CR2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2164\/jandrol.110.011031","volume":"32","author":"A Kadioglu","year":"2011","unstructured":"Kadioglu A, Sanli O, Akman T, et al. Factors affecting the degree of penile deformity in Peyronie disease: an analysis of 1001 patients. J Androl. 2011;32(5):502\u20138.","journal-title":"J Androl"},{"issue":"4","key":"45_CR3","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0022-5347(17)37988-0","volume":"146","author":"MB Lindsay","year":"1991","unstructured":"Lindsay MB, Schain DM, Grambsch P, Benson RC, Beard CM, Kurland LT. The incidence of Peyronie\u2019s disease in Rochester, Minnesota, 1950 through 1984. J Urol. 1991;146(4):1007\u20139.","journal-title":"J Urol"},{"issue":"7","key":"45_CR4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1046\/j.1464-4096.2001.02436.x","volume":"88","author":"U Schwarzer","year":"2001","unstructured":"Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie\u2019s disease: results of a large survey. BJU Int. 2001;88(7):727\u201330.","journal-title":"BJU Int"},{"key":"45_CR5","doi-asserted-by":"crossref","first-page":"282503","DOI":"10.1155\/2011\/282503","volume":"2011","author":"DB Dibenedetti","year":"2011","unstructured":"Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. A population-based study of Peyronie\u2019s disease: prevalence and treatment patterns in the United States. Adv Urol. 2011;2011:282503.","journal-title":"Adv Urol"},{"key":"45_CR6","unstructured":"de la Peyronie F. Sur Quelques Obstacles Qui S\u2019opposent a L\u2019ejaculation Naturelle de la Semence. Mem Acad Chir. 1743;1."},{"key":"45_CR7","unstructured":"Borgogni T. Cyrugia edita et compilata. Venice1498 (written 1265\u20131275)."},{"key":"45_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-59745-161-1_1","volume-title":"Peyronie\u2019s disease: a guide to clinical management","author":"E Akkus","year":"2007","unstructured":"Akkus E. Historical review of Peyronie\u2019s disease: de la Peyronie to Devine. In: Levine LA, editor. Peyronie\u2019s disease: a guide to clinical management. Totowa, NJ: Humana Press; 2007. p. 1\u20138."},{"issue":"6 Pt 1","key":"45_CR9","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1097\/01.ju.0000127744.18878.f1","volume":"171","author":"JP Mulhall","year":"2004","unstructured":"Mulhall JP, Creech SD, Boorjian SA, et al. Subjective and objective analysis of the prevalence of Peyronie\u2019s disease in a population of men presenting for prostate cancer screening. J Urol. 2004;171(6 Pt 1):2350\u20133.","journal-title":"J Urol"},{"issue":"3","key":"45_CR10","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1743-6109.2009.01655.x","volume":"7","author":"R Tal","year":"2010","unstructured":"Tal R, Heck M, Teloken P, Siegrist T, Nelson CJ, Mulhall JP. Peyronie\u2019s disease following radical prostatectomy: incidence and predictors. J Sexual Med. 2010;7(3):1254\u201361.","journal-title":"J Sexual Med"},{"issue":"2","key":"45_CR11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/sj.ijir.3901518","volume":"19","author":"M Arafa","year":"2007","unstructured":"Arafa M, Eid H, El-Badry A, Ezz-Eldine K, Shamloul R. The prevalence of Peyronie\u2019s disease in diabetic patients with erectile dysfunction. Int J Impot Res. 2007;19(2):213\u20137.","journal-title":"Int J Impot Res"},{"issue":"8","key":"45_CR12","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1743-6109.2008.00895.x","volume":"5","author":"CJ Nelson","year":"2008","unstructured":"Nelson CJ, Diblasio C, Kendirci M, Hellstrom W, Guhring P, Mulhall JP. The chronology of depression and distress in men with Peyronie\u2019s disease. J Sex Med. 2008;5(8):1985\u201390. Important work that emphasizes the significant impact that PD has on a man\u2019s mental and psychosocial well-being and the need for a multidisciplinary approach to treatment.","journal-title":"J Sex Med"},{"issue":"3","key":"45_CR13","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1743-6109.2012.02999.x","volume":"10","author":"CJ Nelson","year":"2013","unstructured":"Nelson CJ, Mulhall JP. Psychological impact of Peyronie\u2019s disease: a review. J Sex Med. 2013;10(3):653\u201360.","journal-title":"J Sex Med"},{"issue":"4","key":"45_CR14","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/sm2.45","volume":"2","author":"R Hartzell","year":"2014","unstructured":"Hartzell R. Psychosexual symptoms and treatment of Peyronie\u2019s disease within a collaborative care model. Sex Med. 2014;2(4):168\u201377.","journal-title":"Sex Med"},{"issue":"2","key":"45_CR15","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.juro.2013.01.090","volume":"190","author":"WJ Hellstrom","year":"2013","unstructured":"Hellstrom WJ, Feldman R, Rosen RC, Smith T, Kaufman G, Tursi J. Bother and distress associated with Peyronie\u2019s disease: validation of the Peyronie\u2019s disease questionnaire. J Urol. 2013;190(2):627\u201334. Describes the first quality of life questionnaire validated for use specifically in PD.","journal-title":"J Urol"},{"issue":"3","key":"45_CR16","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1464-410X.2006.05969.x","volume":"97","author":"MD Bjekic","year":"2006","unstructured":"Bjekic MD, Vlajinac HD, Sipetic SB, Marinkovic JM. Risk factors for Peyronie\u2019s disease: a case\u2013control study. BJU Int. 2006;97(3):570\u20134.","journal-title":"BJU Int"},{"issue":"6","key":"45_CR17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0895-4356(98)00015-8","volume":"51","author":"MP Carrieri","year":"1998","unstructured":"Carrieri MP, Serraino D, Palmiotto F, Nucci G, Sasso F. A case\u2013control study on risk factors for Peyronie\u2019s disease. J Clin Epidemiol. 1998;51(6):511\u20135.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"45_CR18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1159\/000049830","volume":"40","author":"G Pera La","year":"2001","unstructured":"La Pera G, Pescatori ES, Calabrese M, et al. Peyronie\u2019s disease: prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50\u201369 years. Eur Urol. 2001;40(5):525\u201330.","journal-title":"Eur Urol"},{"issue":"6","key":"45_CR19","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1111\/j.1743-6109.2009.01250.x","volume":"6","author":"SA Moreno","year":"2009","unstructured":"Moreno SA, Morgentaler A. Testosterone deficiency and Peyronie\u2019s disease: pilot data suggesting a significant relationship. J sex Med. 2009;6(6):1729\u201335.","journal-title":"J sex Med"},{"issue":"11","key":"45_CR20","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/j.1442-2042.2011.02842.x","volume":"18","author":"HJ Nam","year":"2011","unstructured":"Nam HJ, Park HJ, Park NC. Does testosterone deficiency exaggerate the clinical symptoms of Peyronie\u2019s disease? Int J Urol: off J Jpn Urol Assoc. 2011;18(11):796\u2013800.","journal-title":"Int J Urol: off J Jpn Urol Assoc"},{"issue":"3","key":"45_CR21","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/jsm.12805","volume":"12","author":"EW Kirby","year":"2015","unstructured":"Kirby EW, Verges D, Matthews J, Carson CC, Coward RM. Low testosterone has a similar prevalence among men with sexual dysfunction due to either Peyronie\u2019s disease or erectile dysfunction and does not correlate with Peyronie\u2019s Disease severity. J Sex Med. 2015;12(3):690\u20136.","journal-title":"J Sex Med"},{"issue":"12","key":"45_CR22","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1111\/j.1743-6109.2010.01915.x","volume":"7","author":"M Karavitakis","year":"2010","unstructured":"Karavitakis M, Komninos C, Simaioforidis V, et al. The relationship between androgens, regulators of collagen metabolism, and Peyronie\u2019s disease: a case control study. J Sex Med. 2010;7(12):4011\u20137.","journal-title":"J Sex Med"},{"issue":"6","key":"45_CR23","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0022-5347(06)00270-9","volume":"175","author":"JP Mulhall","year":"2006","unstructured":"Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie\u2019s disease. J Urol. 2006;175(6):2115\u20138. discussion 2118. Provides an excellent account of the natural history of PD, debunking the misconception of spontaneous resolution being common.","journal-title":"J Urol"},{"issue":"1","key":"45_CR24","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/01.ju.0000161209.39959.67","volume":"174","author":"KM Azadzoi","year":"2005","unstructured":"Azadzoi KM, Schulman RN, Aviram M, Siroky MB. Oxidative stress in arteriogenic erectile dysfunction: prophylactic role of antioxidants. J Urol. 2005;174(1):386\u201393.","journal-title":"J Urol"},{"issue":"2\u20133","key":"45_CR25","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1385\/ENDO:23:2-3:167","volume":"23","author":"NF Gonzalez-Cadavid","year":"2004","unstructured":"Gonzalez-Cadavid NF, Rajfer J. Therapy of erectile dysfunction: potential future treatments. Endocrine. 2004;23(2\u20133):167\u201376.","journal-title":"Endocrine"},{"issue":"5","key":"45_CR26","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1095\/biolreprod.106.059642","volume":"76","author":"MG Ferrini","year":"2007","unstructured":"Ferrini MG, Kovanecz I, Sanchez S, et al. Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat. Biol Reprod. 2007;76(5):915\u201323.","journal-title":"Biol Reprod"},{"key":"45_CR27","doi-asserted-by":"crossref","first-page":"vi","DOI":"10.1007\/978-1-59745-161-1","volume-title":"Peyronie\u2019s disease: a guide to clinical management","author":"LA Levine","year":"2007","unstructured":"Levine LA. Preface. In: Levine LA, editor. Peyronie\u2019s disease: a guide to clinical management. Totowa, NJ: Humana Press; 2007. p. vi\u2013ix."},{"issue":"1","key":"45_CR28","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0022-5347(01)65359-X","volume":"157","author":"G Brock","year":"1997","unstructured":"Brock G, Hsu GL, Nunes L, von Heyden B, Lue TF. The anatomy of the tunica albuginea in the normal penis and Peyronie\u2019s disease. J Urol. 1997;157(1):276\u201381.","journal-title":"J Urol"},{"issue":"1","key":"45_CR29","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0022-5347(01)65360-6","volume":"157","author":"CJ Davis Jr","year":"1997","unstructured":"Davis Jr CJ. The microscopic pathology of Peyronie\u2019s disease. J Urol. 1997;157(1):282\u20134.","journal-title":"J Urol"},{"issue":"3","key":"45_CR30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1464-410x.1998.00529.x","volume":"81","author":"AI El-Sakka","year":"1998","unstructured":"El-Sakka AI, Hassan MU, Nunes L, Bhatnagar RS, Yen TS, Lue TF. Histological and ultrastructural alterations in an animal model of Peyronie\u2019s disease. Br J Urol. 1998;81(3):445\u201352.","journal-title":"Br J Urol"},{"issue":"1","key":"45_CR31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0022-5347(01)65367-9","volume":"157","author":"KD Somers","year":"1997","unstructured":"Somers KD, Dawson DM. Fibrin deposition in Peyronie\u2019s disease plaque. J Urol. 1997;157(1):311\u20135.","journal-title":"J Urol"},{"issue":"1","key":"45_CR32","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0022-5347(01)65361-8","volume":"157","author":"CJ Devine Jr","year":"1997","unstructured":"Devine Jr CJ, Somers KD, Jordan SG, Schlossberg SM. Proposal: trauma as the cause of the Peyronie\u2019s lesion. J Urol. 1997;157(1):285\u201390.","journal-title":"J Urol"},{"issue":"1","key":"45_CR33","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0022-5347(01)65364-3","volume":"157","author":"RF Diegelmann","year":"1997","unstructured":"Diegelmann RF. Cellular and biochemical aspects of normal and abnormal wound healing: an overview. J Urol. 1997;157(1):298\u2013302.","journal-title":"J Urol"},{"issue":"4","key":"45_CR34","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/01.ju.0000053800.62741.fe","volume":"169","author":"SS Gholami","year":"2003","unstructured":"Gholami SS, Gonzalez-Cadavid NF, Lin CS, Rajfer J, Lue TF. Peyronie\u2019s disease: a review. J Urol. 2003;169(4):1234\u201341.","journal-title":"J Urol"},{"issue":"6","key":"45_CR35","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s11934-004-0074-y","volume":"5","author":"M Jalkut","year":"2004","unstructured":"Jalkut M, Gonzalez-Cadavid N, Rajfer J. New discoveries in the basic science understanding of Peyronie\u2019s disease. Curr Urol Rep. 2004;5(6):478\u201384.","journal-title":"Curr Urol Rep"},{"issue":"2","key":"45_CR36","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00005392-200102000-00016","volume":"165","author":"JP Mulhall","year":"2001","unstructured":"Mulhall JP, Thom J, Lubrano T, Shankey TV. Basic fibroblast growth factor expression in Peyronie\u2019s disease. J Urol. 2001;165(2):419\u201323.","journal-title":"J Urol"},{"issue":"6","key":"45_CR37","first-page":"291","volume":"2","author":"NF Gonzalez-Cadavid","year":"2005","unstructured":"Gonzalez-Cadavid NF, Rajfer J. Mechanisms of disease: new insights into the cellular and molecular pathology of Peyronie\u2019s disease. Nature clinical practice. Urology. 2005;2(6):291\u20137.","journal-title":"Urology"},{"issue":"2","key":"45_CR38","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1743-6109.2008.01104.x","volume":"6","author":"NF Gonzalez-Cadavid","year":"2009","unstructured":"Gonzalez-Cadavid NF, Rajfer J. Experimental models of Peyronie\u2019s disease. Implications for new therapies. J Sex Med. 2009;6(2):303\u201313.","journal-title":"J Sex Med"},{"issue":"6","key":"45_CR39","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0022-5347(01)68236-3","volume":"158","author":"AI El-Sakka","year":"1997","unstructured":"El-Sakka AI, Hassoba HM, Chui RM, Bhatnagar RS, Dahiya R, Lue TF. An animal model of Peyronie\u2019s-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol. 1997;158(6):2284\u201390.","journal-title":"J Urol"},{"issue":"6","key":"45_CR40","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1095\/biolreprod.105.041038","volume":"73","author":"D Vernet","year":"2005","unstructured":"Vernet D, Nolazco G, Cantini L, et al. Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implications for Peyronie disease. Biol Reprod. 2005;73(6):1199\u2013210.","journal-title":"Biol Reprod"},{"issue":"4","key":"45_CR41","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1089-8603(02)00124-6","volume":"7","author":"D Vernet","year":"2002","unstructured":"Vernet D, Ferrini MG, Valente EG, et al. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie\u2019s fibrotic plaque and in its rat model. Nitric oxide : Biol Chem \/ Off J Nitric Oxide Soc. 2002;7(4):262\u201376.","journal-title":"Nitric oxide : Biol Chem \/ Off J Nitric Oxide Soc"},{"issue":"9","key":"45_CR42","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1046\/j.1464-410X.2003.04224.x","volume":"91","author":"HH Davila","year":"2003","unstructured":"Davila HH, Ferrini MG, Rajfer J, Gonzalez-Cadavid NF. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie\u2019s disease. BJU Int. 2003;91(9):830\u20138.","journal-title":"BJU Int"},{"issue":"5","key":"45_CR43","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1097\/00005392-199805000-00097","volume":"159","author":"AI El-Sakka","year":"1998","unstructured":"El-Sakka AI, Selph CA, Yen TS, Dahiya R, Lue TF. The effect of surgical trauma on rat tunica albuginea. J Urol. 1998;159(5):1700\u20137.","journal-title":"J Urol"},{"issue":"1","key":"45_CR44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0022-5347(17)56238-2","volume":"122","author":"MK Willscher","year":"1979","unstructured":"Willscher MK, Cwazka WF, Novicki DE. The association of histocompatibility antigens of the B7 cross-reacting group with Peyronie\u2019s disease. J Urol. 1979;122(1):34\u20135.","journal-title":"J Urol"},{"issue":"3","key":"45_CR45","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1399-0039.1991.tb02021.x","volume":"38","author":"R Rompel","year":"1991","unstructured":"Rompel R, Weidner W, Mueller-Eckhardt G. HLA association of idiopathic Peyronie\u2019s disease: an indication of autoimmune phenomena in etiopathogenesis? Tissue Antigens. 1991;38(3):104\u20136.","journal-title":"Tissue Antigens"},{"issue":"4","key":"45_CR46","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0022-5347(01)65579-4","volume":"156","author":"DA Nachtsheim","year":"1996","unstructured":"Nachtsheim DA, Rearden A. Peyronie\u2019s disease is associated with an HLA class II antigen, HLA-DQ5, implying an autoimmune etiology. J Urol. 1996;156(4):1330\u20134.","journal-title":"J Urol"},{"issue":"1","key":"45_CR47","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0022-5347(17)52751-2","volume":"128","author":"LM Nyberg Jr","year":"1982","unstructured":"Nyberg Jr LM, Bias WB, Hochberg MC, Walsh PC. Identification of an inherited form of Peyronie\u2019s disease with autosomal dominant inheritance and association with Dupuytren\u2019s contracture and histocompatibility B7 cross-reacting antigens. J Urol. 1982;128(1):48\u201351.","journal-title":"J Urol"},{"issue":"4 Pt 1","key":"45_CR48","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/01.ju.0000076488.89748.e1","volume":"170","author":"EW Hauck","year":"2003","unstructured":"Hauck EW, Hauptmann A, Weidner W, Bein G, Hackstein H. Prospective analysis of HLA classes I and II antigen frequency in patients with Peyronie\u2019s disease. J Urol. 2003;170(4 Pt 1):1443\u20136.","journal-title":"J Urol"},{"issue":"6","key":"45_CR49","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0022-5347(17)54302-5","volume":"127","author":"MS Leffell","year":"1982","unstructured":"Leffell MS, Devine Jr CJ, Horton CE, et al. Non-association of Peyronie\u2019s disease with HLA B7 cross-reactive antigens. J Urol. 1982;127(6):1223\u20134.","journal-title":"J Urol"},{"issue":"Suppl 4","key":"45_CR50","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1038\/sj.ijir.3900591","volume":"12","author":"MB Noss","year":"2000","unstructured":"Noss MB, Day NS, Christ GJ, Melman A. The genetics and immunology of Peyronie\u2019s disease. Int J Impot Res. 2000;12 Suppl 4:S127\u201332.","journal-title":"Int J Impot Res"},{"issue":"2","key":"45_CR51","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.urology.2004.04.006","volume":"64","author":"A Qian","year":"2004","unstructured":"Qian A, Meals RA, Rajfer J, Gonzalez-Cadavid NF. Comparison of gene expression profiles between Peyronie\u2019s disease and Dupuytren\u2019s contracture. Urology. 2004;64(2):399\u2013404. Provides evidence that PD and DD may share a common pathophysiology.","journal-title":"Urology"},{"issue":"1","key":"45_CR52","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0165-4608(96)00430-X","volume":"99","author":"R Casalone","year":"1997","unstructured":"Casalone R, Mazzola D, Meroni E, et al. Cytogenetic and interphase cytogenetic analyses reveal chromosome instability but no clonal trisomy 8 in Dupuytren contracture. Cancer Genet Cytogenet. 1997;99(1):73\u20136.","journal-title":"Cancer Genet Cytogenet"},{"issue":"2","key":"45_CR53","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0165-4608(98)00126-5","volume":"108","author":"P Dal Cin","year":"1999","unstructured":"Dal Cin P, De Smet L, Sciot R, Van Damme B, Van den Berghe H. Trisomy 7 and trisomy 8 in dividing and non-dividing tumor cells in Dupuytren\u2019s disease. Cancer Genet Cytogenet. 1999;108(2):137\u201340.","journal-title":"Cancer Genet Cytogenet"},{"issue":"3","key":"45_CR54","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/sj.ijir.3901170","volume":"16","author":"JP Mulhall","year":"2004","unstructured":"Mulhall JP, Nicholson B, Pierpaoli S, Lubrano T, Shankey TV. Chromosomal instability is demonstrated by fibroblasts derived from the tunica of men with Peyronie\u2019s disease. Int J Impot Res. 2004;16(3):288\u201393.","journal-title":"Int J Impot Res"},{"issue":"2","key":"45_CR55","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sj.ijir.3901183","volume":"16","author":"JP Mulhall","year":"2004","unstructured":"Mulhall JP, Martin DJ, Lubrano T, et al. Peyronie\u2019s disease fibroblasts demonstrate tumorigenicity in the severe combined immunodeficient (SCID) mouse model. Int J Impot Res. 2004;16(2):99\u2013104. Reveals a link between PD and malignancy, which warrants further investigation.","journal-title":"Int J Impot Res"},{"issue":"1","key":"45_CR56","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1897-4287-12-6","volume":"12","author":"A Zyluk","year":"2014","unstructured":"Zyluk A, Paszkowska-Szczur K, Gupta S, Scott RJ, Lubinski J, Debniak T. Dupuytren\u2019s disease and the risk of malignant neoplasms. Hereditary Cancer Clin Pract. 2014;12(1):6.","journal-title":"Hereditary Cancer Clin Pract"},{"issue":"4","key":"45_CR57","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1007\/s11033-014-3121-x","volume":"41","author":"T Xiong","year":"2014","unstructured":"Xiong T, Yang J, Wang H, et al. The association between the Lys751Gln polymorphism in the XPD gene and the risk of bladder cancer. Mol Biol Rep. 2014;41(4):2629\u201334.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"45_CR58","first-page":"257","volume":"24","author":"W Gao","year":"2010","unstructured":"Gao W, Romkes M, Zhong S, et al. Genetic polymorphisms in the DNA repair genes XPD and XRCC1, p53 gene mutations and bladder cancer risk. Oncol Rep. 2010;24(1):257\u201362.","journal-title":"Oncol Rep"},{"issue":"2","key":"45_CR59","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/dna.2011.1283","volume":"31","author":"RC Sobti","year":"2012","unstructured":"Sobti RC, Kaur S, Sharma VL, Singh SK, Hosseini SA, Kler R. Susceptibility of XPD and RAD51 genetic variants to carcinoma of urinary bladder in North Indian population. DNA Cell Biol. 2012;31(2):199\u2013210.","journal-title":"DNA Cell Biol"},{"issue":"1","key":"45_CR60","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0022-5347(17)61894-9","volume":"103","author":"JL Williams","year":"1970","unstructured":"Williams JL, Thomas GG. The natural history of Peyronie\u2019s disease. J Urol. 1970;103(1):75\u20136.","journal-title":"J Urol"},{"issue":"6","key":"45_CR61","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0022-5347(17)39746-X","volume":"144","author":"MK Gelbard","year":"1990","unstructured":"Gelbard MK, Dorey F, James K. The natural history of Peyronie\u2019s disease. J Urol. 1990;144(6):1376\u20139.","journal-title":"J Urol"},{"issue":"1","key":"45_CR62","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bju.12346","volume":"113","author":"BM Berookhim","year":"2014","unstructured":"Berookhim BM, Choi J, Alex B, Mulhall JP. Deformity stabilization and improvement in men with untreated Peyronie\u2019s disease. BJU Int. 2014;113(1):133\u20136.","journal-title":"BJU Int"},{"issue":"3","key":"45_CR63","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0022-5347(05)64578-8","volume":"168","author":"A Kadioglu","year":"2002","unstructured":"Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S. A retrospective review of 307 men with Peyronie\u2019s disease. J Urol. 2002;168(3):1075\u20139.","journal-title":"J Urol"},{"key":"45_CR64","doi-asserted-by":"crossref","unstructured":"Jordan GHM, K. A. Peyronie\u2019s disease. In: Kavoussi LRNACPCAWAJ, ed. Campbell-Walsh Urology. Vol 1. 10 ed. Philadelphia: Elsevier Saunders; 2012:792\u2013809.","DOI":"10.1016\/B978-1-4160-6911-9.00028-1"},{"key":"45_CR65","doi-asserted-by":"crossref","unstructured":"Wilson SKaC, C. C. Surgical straightening with penile prosthesis. In: Levine LA, ed. Peyronie\u2019s disease: a guide to clinical management. Totowa, NJ: Humana Press; 2007:249\u2013258.","DOI":"10.1007\/978-1-59745-161-1"},{"issue":"1","key":"45_CR66","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-5347(05)00063-7","volume":"175","author":"JM Greenfield","year":"2006","unstructured":"Greenfield JM, Lucas S, Levine LA. Factors affecting the loss of length associated with tunica albuginea plication for correction of penile curvature. J Urol. 2006;175(1):238\u201341. Provides important outcomes data for tunical plication and also provides evidence that patients\u2019 description of their own deformity is inaccurate, supporting objective measurement of deformity on erect penile exam.","journal-title":"J Urol"},{"issue":"1","key":"45_CR67","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1743-6109.2006.00404.x","volume":"4","author":"M Ohebshalom","year":"2007","unstructured":"Ohebshalom M, Mulhall J, Guhring P, Parker M. Measurement of penile curvature in Peyronie\u2019s disease patients: comparison of three methods. J Sex Med. 2007;4(1):199\u2013203.","journal-title":"J Sex Med"},{"issue":"3","key":"45_CR68","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s11930-014-0023-9","volume":"6","author":"AJ Pastuszak","year":"2014","unstructured":"Pastuszak AJ. Current diagnosis and management of erectile dysfunction. Curr Sex Health Rep. 2014;6(3):164\u201376.","journal-title":"Curr Sex Health Rep"},{"key":"45_CR69","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-1-59745-161-1_10","volume-title":"Peyronie\u2019s disease: a guide to clinical management","author":"V Mirone","year":"2007","unstructured":"Mirone V. Combination nonsurgical therapy. In: Levine LA, editor. Peyronie\u2019s disease: a guide to clinical management. Totowa, NJ: Humana Press; 2007. p. 111\u20139."},{"issue":"5","key":"45_CR70","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/ijir.2010.20","volume":"22","author":"MR Safarinejad","year":"2010","unstructured":"Safarinejad MR. Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie\u2019s disease: a double-blind, placebo-controlled randomized study. Int J Impot Res. 2010;22(5):298\u2013309.","journal-title":"Int J Impot Res"},{"issue":"4","key":"45_CR71","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1046\/j.1464-410X.2000.00827.x","volume":"86","author":"J Husain","year":"2000","unstructured":"Husain J, Lynn NN, Jones DK, Collins GN, O\u2019Reilly PH. Extracorporeal shock wave therapy in the management of Peyronie\u2019s disease: initial experience. BJU Int. 2000;86(4):466\u20138.","journal-title":"BJU Int"},{"key":"45_CR72","first-page":"6","volume":"2013","author":"M Ballerini","year":"2013","unstructured":"Ballerini M, Baronzio GF, Capit, et al. Androtherm application for the Peyronie\u2019s disease. Conf Papers in Med. 2013;2013:6.","journal-title":"Conf Papers in Med"},{"issue":"1","key":"45_CR73","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/00365597609179649","volume":"10","author":"J Bystrom","year":"1976","unstructured":"Bystrom J. Induration penis plastica. Experience of treatment with procarbazine Natulan. Scand J Urol Nephrol. 1976;10(1):21\u20135.","journal-title":"Scand J Urol Nephrol"},{"issue":"2","key":"45_CR74","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1464-410X.1978.tb03038.x","volume":"50","author":"RJ Morgan","year":"1978","unstructured":"Morgan RJ, Pryor JP. Procarbazine (Natulan) in the treatment of Peyronie\u2019s disease. Br J Urol. 1978;50(2):111\u20133.","journal-title":"Br J Urol"},{"issue":"2","key":"45_CR75","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1464-410X.1975.tb03951.x","volume":"47","author":"W Oosterlinck","year":"1975","unstructured":"Oosterlinck W, Renders G. Treatment of Peyronie\u2019s disease with procarbazine. Br J Urol. 1975;47(2):219\u201320.","journal-title":"Br J Urol"},{"issue":"3","key":"45_CR76","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1590\/S1677-55382004000300004","volume":"30","author":"JA Claro","year":"2004","unstructured":"Claro JA, Passerotti CC, Figueiredo Neto AC, Nardozza Jr A, Ortiz V, Srougi M. An alternative non-invasive treatment for Peyronie\u2019s disease. Int Braz J Urol : Off J Braz Soc Urol. 2004;30(3):199\u2013204. discussion 204.","journal-title":"Int Braz J Urol : Off J Braz Soc Urol"},{"issue":"3","key":"45_CR77","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1442-2042.2006.01270.x","volume":"13","author":"K Hashimoto","year":"2006","unstructured":"Hashimoto K, Hisasue S, Kato R, Kobayashi K, Shimizu T, Tsukamoto T. Outcome analysis for conservative management of Peyronie\u2019s disease. Int J Urol : Off J Jpn Urol Assoc. 2006;13(3):244\u20137.","journal-title":"Int J Urol : Off J Jpn Urol Assoc"},{"issue":"5","key":"45_CR78","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.urology.2005.11.005","volume":"67","author":"T Inal","year":"2006","unstructured":"Inal T, Tokatli Z, Akand M, Ozdiler E, Yaman O. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie\u2019s disease: a randomized and prospective study. Urology. 2006;67(5):1038\u201342.","journal-title":"Urology"},{"issue":"4 Pt 1","key":"45_CR79","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.juro.2007.05.162","volume":"178","author":"MR Safarinejad","year":"2007","unstructured":"Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie\u2019s disease: a double-blind, placebo controlled, randomized study. J Urol. 2007;178(4 Pt 1):1398\u2013403. discussion 1403.","journal-title":"J Urol"},{"issue":"4","key":"45_CR80","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.ijir.3900414","volume":"11","author":"SK Ahuja","year":"1999","unstructured":"Ahuja SK, Sikka SC, Hellstrom WJ. Stimulation of collagen production in an in vitro model for Peyronie\u2019s disease. Int J Impot Res. 1999;11(4):207\u201312.","journal-title":"Int J Impot Res"},{"issue":"3","key":"45_CR81","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2012.05.040","volume":"62","author":"K Hatzimouratidis","year":"2012","unstructured":"Hatzimouratidis K, Eardley I, Giuliano F, et al. EAU guidelines on penile curvature. Eur Urol. 2012;62(3):543\u201352. Summarizes the EAU guidelines for management of PD, which provided much-needed guidance that was previously lacking.","journal-title":"Eur Urol"},{"issue":"1","key":"45_CR82","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1464-410x.2001.02241.x","volume":"88","author":"G Biagiotti","year":"2001","unstructured":"Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie\u2019s disease: a preliminary report. BJU Int. 2001;88(1):63\u20137.","journal-title":"BJU Int"},{"issue":"6","key":"45_CR83","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1464-410X.1992.tb15836.x","volume":"70","author":"DJ Ralph","year":"1992","unstructured":"Ralph DJ, Brooks MD, Bottazzo GF, Pryor JP. The treatment of Peyronie\u2019s disease with tamoxifen. Br J Urol. 1992;70(6):648\u201351.","journal-title":"Br J Urol"},{"issue":"6","key":"45_CR84","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/S0022-5347(05)68087-1","volume":"162","author":"C Teloken","year":"1999","unstructured":"Teloken C, Rhoden EL, Grazziotin TM, Ros CT, Sogari PR, Souto CA. Tamoxifen versus placebo in the treatment of Peyronie\u2019s disease. J Urol. 1999;162(6):2003\u20135.","journal-title":"J Urol"},{"issue":"6","key":"45_CR85","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1111\/j.1743-6109.2009.01235.x","volume":"6","author":"MR Safarinejad","year":"2009","unstructured":"Safarinejad MR. Efficacy and safety of omega-3 for treatment of early-stage Peyronie\u2019s disease: a prospective, randomized, double-blind placebo-controlled study. J Sex Med. 2009;6(6):1743\u201354.","journal-title":"J Sex Med"},{"issue":"4","key":"45_CR86","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2165\/00003495-200767040-00004","volume":"67","author":"LW Trost","year":"2007","unstructured":"Trost LW, Gur S, Hellstrom WJ. Pharmacological management of Peyronie\u2019s disease. Drugs. 2007;67(4):527\u201345.","journal-title":"Drugs"},{"issue":"6","key":"45_CR87","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1111\/j.1743-6109.2010.01790.x","volume":"7","author":"AW Shindel","year":"2010","unstructured":"Shindel AW, Lin G, Ning H, et al. Pentoxifylline attenuates transforming growth factor-beta1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix. J sex Med. 2010;7(6):2077\u201385.","journal-title":"J sex Med"},{"issue":"4","key":"45_CR88","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.niox.2003.12.002","volume":"9","author":"EG Valente","year":"2003","unstructured":"Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie\u2019s fibrotic plaque and related fibroblast cultures. Nitric oxide : Biol Chem \/ Off J Nitric Oxide Soc. 2003;9(4):229\u201344.","journal-title":"Nitric oxide : Biol Chem \/ Off J Nitric Oxide Soc"},{"issue":"2","key":"45_CR89","first-page":"111","volume":"3","author":"WO Brant","year":"2006","unstructured":"Brant WO, Dean RC, Lue TF. Treatment of Peyronie\u2019s disease with oral pentoxifylline. Nature clinical practice. Urology. 2006;3(2):111\u20135. quiz 116.","journal-title":"Urology"},{"issue":"1","key":"45_CR90","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/bju.12634","volume":"114","author":"GH Jordan","year":"2014","unstructured":"Jordan GH, Carson CC, Lipshultz LI. Minimally invasive treatment of Peyronie\u2019s disease: evidence-based progress. BJU Int. 2014;114(1):16\u201324.","journal-title":"BJU Int"},{"issue":"6","key":"45_CR91","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/S0022-5347(05)68868-4","volume":"161","author":"AI El-Sakka","year":"1999","unstructured":"El-Sakka AI, Bakircioglu ME, Bhatnagar RS, Yen TS, Dahiya R, Lue TF. The effects of colchicine on a Peyronie\u2019s-like condition in an animal model. J Urol. 1999;161(6):1980\u20133.","journal-title":"J Urol"},{"issue":"2","key":"45_CR92","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0090-4295(94)80155-X","volume":"44","author":"E Akkus","year":"1994","unstructured":"Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue TF. Is colchicine effective in Peyronie\u2019s disease? A pilot study. Urology. 1994;44(2):291\u20135.","journal-title":"Urology"},{"issue":"3","key":"45_CR93","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/sj.ijir.3900519","volume":"12","author":"A Kadioglu","year":"2000","unstructured":"Kadioglu A, Tefekli A, Koksal T, Usta M, Erol H. Treatment of Peyronie\u2019s disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int J Impot Res. 2000;12(3):169\u201375.","journal-title":"Int J Impot Res"},{"issue":"3","key":"45_CR94","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.ijir.3901185","volume":"16","author":"MR Safarinejad","year":"2004","unstructured":"Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie\u2019s disease: a randomized double-blind, placebo-controlled study. Int J Impot Res. 2004;16(3):238\u201343.","journal-title":"Int J Impot Res"},{"issue":"6","key":"45_CR95","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0022-5347(17)66108-1","volume":"81","author":"CJ Zarafonetis","year":"1959","unstructured":"Zarafonetis CJ, Horrax TM. Treatment of Peyronie\u2019s disease with potassium para-aminobenzoate (POTABA). J Urol. 1959;81(6):770\u20132.","journal-title":"J Urol"},{"issue":"4","key":"45_CR96","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.eururo.2004.12.022","volume":"47","author":"W Weidner","year":"2005","unstructured":"Weidner W, Hauck EW, Schnitker J, Urologists PsDSGoAGoG. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie\u2019s disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47(4):530\u20135. discussion 535\u2013536.","journal-title":"Eur Urol"},{"issue":"9","key":"45_CR97","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1046\/j.1464-410X.2003.04242.x","volume":"91","author":"SM Stasi Di","year":"2003","unstructured":"Di Stasi SM, Giannantoni A, Capelli G, et al. Transdermal electromotive administration of verapamil and dexamethasone for Peyronie\u2019s disease. BJU Int. 2003;91(9):825\u20139.","journal-title":"BJU Int"},{"issue":"4","key":"45_CR98","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/01.ju.0000116450.82816.2c","volume":"171","author":"SM Stasi Di","year":"2004","unstructured":"Di Stasi SM, Giannantoni A, Stephen RL, et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie\u2019s disease. J Urol. 2004;171(4):1605\u20138.","journal-title":"J Urol"},{"issue":"3","key":"45_CR99","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.juro.2006.10.065","volume":"177","author":"JM Greenfield","year":"2007","unstructured":"Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie\u2019s disease: a double-blind, placebo controlled trial. J Urol. 2007;177(3):972\u20135.","journal-title":"J Urol"},{"issue":"1","key":"45_CR100","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.2047-2927.2012.00018.x","volume":"1","author":"AR Mehrsai","year":"2013","unstructured":"Mehrsai AR, Namdari F, Salavati A, Dehghani S, Allameh F, Pourmand G. Comparison of transdermal electromotive administration of verapamil and dexamethasone versus intra-lesional injection for Peyronie\u2019s disease. Andrology. 2013;1(1):129\u201332.","journal-title":"Andrology"},{"issue":"6","key":"45_CR101","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.urology.2007.02.042","volume":"69","author":"NE Bennett","year":"2007","unstructured":"Bennett NE, Guhring P, Mulhall JP. Intralesional verapamil prevents the progression of Peyronie\u2019s disease. Urology. 2007;69(6):1181\u20134.","journal-title":"Urology"},{"issue":"5","key":"45_CR102","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.urology.2007.01.080","volume":"69","author":"G Cavallini","year":"2007","unstructured":"Cavallini G, Modenini F, Vitali G. Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie\u2019s disease. Urology. 2007;69(5):950\u20134.","journal-title":"Urology"},{"issue":"1","key":"45_CR103","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.juro.2012.08.191","volume":"189","author":"E Chung","year":"2013","unstructured":"Chung E, Garcia F, Young LD, Solomon M, Brock GB. A comparative study of the efficacy of intralesional verapamil versus normal saline injection in a novel Peyronie disease animal model: assessment of immunohistopathological changes and erectile function outcome. J Urol. 2013;189(1):380\u20134.","journal-title":"J Urol"},{"key":"45_CR104","unstructured":"Heidari M, Nejadi JR, Ghate A, Delfan B, Iran-Pour E. Evaluation of intralesional injection of verapamil in treatment of Peyronie\u2019s disease. JPMA. J Pak Med Assoc. 2010;60(4):291\u2013293."},{"issue":"2","key":"45_CR105","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0022-5347(05)64691-5","volume":"168","author":"LA Levine","year":"2002","unstructured":"Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie\u2019s disease. J Urol. 2002;168(2):621\u20135. discussion 625\u2013626.","journal-title":"J Urol"},{"issue":"6","key":"45_CR106","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/S0022-5347(17)35291-6","volume":"151","author":"LA Levine","year":"1994","unstructured":"Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie\u2019s disease. J Urol. 1994;151(6):1522\u20134.","journal-title":"J Urol"},{"issue":"9","key":"45_CR107","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1111\/j.1464-410X.2010.10029.x","volume":"108","author":"DJ Moskovic","year":"2011","unstructured":"Moskovic DJ, Alex B, Choi JM, Nelson CJ, Mulhall JP. Defining predictors of response to intralesional verapamil injection therapy for Peyronie\u2019s disease. BJU Int. 2011;108(9):1485\u20139.","journal-title":"BJU Int"},{"issue":"4","key":"45_CR108","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/02656730500133892","volume":"21","author":"G Perugia","year":"2005","unstructured":"Perugia G, Liberti M, Vicini P, Colistro F, Gentile V. Role of hyperthermia in the treatment of Peyronie\u2019s disease: a preliminary study. Int J Hyperthermia : Off J Eur Soc Hyperthermic Oncol, N Am Hyperthermia Group. 2005;21(4):367\u201374.","journal-title":"Int J Hyperthermia : Off J Eur Soc Hyperthermic Oncol, N Am Hyperthermia Group"},{"issue":"4","key":"45_CR109","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0090-4295(97)00700-0","volume":"51","author":"J Rehman","year":"1998","unstructured":"Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie\u2019s disease plaque: a long-term single-blind study. Urology. 1998;51(4):620\u20136.","journal-title":"Urology"},{"issue":"3","key":"45_CR110","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11255-009-9522-4","volume":"41","author":"M Shirazi","year":"2009","unstructured":"Shirazi M, Haghpanah AR, Badiee M, Afrasiabi MA, Haghpanah S. Effect of intralesional verapamil for treatment of Peyronie\u2019s disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol. 2009;41(3):467\u201371.","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"45_CR111","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.2047-2927.2012.00007.x","volume":"1","author":"G Paulis","year":"2013","unstructured":"Paulis G, Brancato T, D\u2019Ascenzo R, et al. Efficacy of vitamin E in the conservative treatment of Peyronie\u2019s disease: legend or reality? A controlled study of 70 cases. Andrology. 2013;1(1):120\u20138.","journal-title":"Andrology"},{"issue":"1","key":"45_CR112","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/1871528111312010009","volume":"12","author":"G Paulis","year":"2013","unstructured":"Paulis G, Cavallini G, Brancato T, Alvaro R. Peironimev-Plus(R) in the treatment of chronic inflammation of tunica albuginea (Peyronie\u2019s disease). Results of a controlled study. Inflamm Allergy Drug Targets. 2013;12(1):61\u20137.","journal-title":"Inflamm Allergy Drug Targets"},{"issue":"2","key":"45_CR113","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1743-6109.2006.00417.x","volume":"4","author":"WP Fitch 3rd","year":"2007","unstructured":"Fitch 3rd WP, Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie\u2019s disease\u2014a placebo-controlled pilot study. J Sex Med. 2007;4(2):477\u201384.","journal-title":"J Sex Med"},{"issue":"1\u20132","key":"45_CR114","first-page":"189","volume":"34","author":"S Lenk","year":"1994","unstructured":"Lenk S, Schonberger B. Penile deviation\u2014our therapeutic concept. Acta Chir Hung. 1994;34(1\u20132):189\u201394.","journal-title":"Acta Chir Hung"},{"issue":"2","key":"45_CR115","first-page":"250","volume":"4","author":"G Bartsch","year":"1981","unstructured":"Bartsch G, Menander-Huber KB, Huber W, Marberger H. Orgotein, a new drug for the treatment of Peyronie\u2019s disease. Eur J Rheumatol Inflamm. 1981;4(2):250\u20139.","journal-title":"Eur J Rheumatol Inflamm"},{"issue":"6","key":"45_CR116","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000473262","volume":"7","author":"H Gustafson","year":"1981","unstructured":"Gustafson H, Johansson B, Edsmyr F. Peyronie\u2019s disease: experience of local treatment with Orgotein. Eur Urol. 1981;7(6):346\u20138.","journal-title":"Eur Urol"},{"issue":"3","key":"45_CR117","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000049797","volume":"40","author":"CR Riedl","year":"2001","unstructured":"Riedl CR, Plas E, Vorauer K, Vcelar B, Wagner A, Pfluger H. Pilot study on liposomal recombinant human superoxide dismutase for the treatment of Peyronie\u2019s disease. Eur Urol. 2001;40(3):343\u20138. discussion 348\u2013349.","journal-title":"Eur Urol"},{"issue":"4","key":"45_CR118","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.eururo.2005.04.011","volume":"48","author":"CR Riedl","year":"2005","unstructured":"Riedl CR, Sternig P, Galle G, et al. Liposomal recombinant human superoxide dismutase for the treatment of Peyronie\u2019s disease: a randomized placebo-controlled double-blind prospective clinical study. Eur Urol. 2005;48(4):656\u201361.","journal-title":"Eur Urol"},{"issue":"4","key":"45_CR119","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/j.1939-4640.1999.tb02539.x","volume":"20","author":"S Ahuja","year":"1999","unstructured":"Ahuja S, Bivalacqua TJ, Case J, Vincent M, Sikka SC, Hellstrom WJ. A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie\u2019s disease. J Androl. 1999;20(4):444\u20138.","journal-title":"J Androl"},{"issue":"7","key":"45_CR120","first-page":"665","volume":"53","author":"R Astorga","year":"2000","unstructured":"Astorga R, Cantero O, Contreras D, et al. Intralesional recombinant interferon alpha-2b in Peyronie\u2019s disease. Arch Esp Urol. 2000;53(7):665\u201371.","journal-title":"Arch Esp Urol"},{"issue":"7","key":"45_CR121","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1046\/j.1464-410x.2001.02139.x","volume":"87","author":"M Brake","year":"2001","unstructured":"Brake M, Loertzer H, Horsch R, Keller H. Treatment of Peyronie\u2019s disease with local interferon-alpha 2b. BJU Int. 2001;87(7):654\u20137.","journal-title":"BJU Int"},{"issue":"1","key":"45_CR122","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/01.SMJ.0000056658.60032.D3","volume":"97","author":"G Dang","year":"2004","unstructured":"Dang G, Matern R, Bivalacqua TJ, Sikka S, Hellstrom WJ. Intralesional interferon-alpha-2B injections for the treatment of Peyronie\u2019s disease. South Med J. 2004;97(1):42\u20136.","journal-title":"South Med J"},{"issue":"1","key":"45_CR123","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1464-410X.1997.02849.x","volume":"79","author":"IS Judge","year":"1997","unstructured":"Judge IS, Wisniewski ZS. Intralesional interferon in the treatment of Peyronie\u2019s disease: a pilot study. Br J Urol. 1997;79(1):40\u20132.","journal-title":"Br J Urol"},{"issue":"4","key":"45_CR124","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/BF02551115","volume":"29","author":"O Polat","year":"1997","unstructured":"Polat O, Gul O, Ozbey I, Ozdikici M, Bayraktar Y. Peyronie\u2019s disease: intralesional treatment with interferon alpha-2A and evaluation of the results by magnetic resonance imaging. Int Urol Nephrol. 1997;29(4):465\u201371.","journal-title":"Int Urol Nephrol"},{"issue":"6","key":"45_CR125","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/j.juro.2013.05.022","volume":"190","author":"LW Trost","year":"2013","unstructured":"Trost LW, Ates E, Powers M, Sikka S, Hellstrom WJ. Outcomes of intralesional interferon-alpha2B for the treatment of Peyronie disease. J Urol. 2013;190(6):2194\u20139.","journal-title":"J Urol"},{"issue":"3","key":"45_CR126","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000475057","volume":"28","author":"HE Wegner","year":"1995","unstructured":"Wegner HE, Andresen R, Knipsel HH, Miller K. Treatment of Peyronie\u2019s disease with local interferon-alpha 2b. Eur Urol. 1995;28(3):236\u201340.","journal-title":"Eur Urol"},{"issue":"1","key":"45_CR127","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0022-5347(06)00517-9","volume":"176","author":"WJ Hellstrom","year":"2006","unstructured":"Hellstrom WJ, Kendirci M, Matern R, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie\u2019s disease. J Urol. 2006;176(1):394\u20138.","journal-title":"J Urol"},{"issue":"5","key":"45_CR128","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1743-6109.2005.00110.x","volume":"2","author":"M Kendirci","year":"2005","unstructured":"Kendirci M, Usta MF, Matern RV, Nowfar S, Sikka SC, Hellstrom WJ. The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie\u2019s disease. J Sex Med. 2005;2(5):709\u201315.","journal-title":"J Sex Med"},{"key":"45_CR129","doi-asserted-by":"crossref","unstructured":"Lipshultz LI, Goldstein I, Seftel AD, et al. Clinical efficacy of collagenase clostridium histolyticum in the treatment of Peyronie\u2019s disease by subgroups: results from two large, double-blind, randomized, placebo-controlled, phase 3 studies. BJU international. 2015.","DOI":"10.1111\/bju.13096"},{"issue":"1","key":"45_CR130","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","volume":"190","author":"M Gelbard","year":"2013","unstructured":"Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190(1):199\u2013207. Findings of the IMPRESS trial, demonstrating safety and efficacy of clostridial collagenase in PD. This biologic agent is the only FDA-approved medical treatment for PD.","journal-title":"J Urol"},{"issue":"6","key":"45_CR131","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/j.juro.2012.01.032","volume":"187","author":"M Gelbard","year":"2012","unstructured":"Gelbard M, Lipshultz LI, Tursi J, Smith T, Kaufman G, Levine LA. Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol. 2012;187(6):2268\u201374.","journal-title":"J Urol"},{"issue":"1","key":"45_CR132","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0022-5347(17)35998-0","volume":"149","author":"MK Gelbard","year":"1993","unstructured":"Gelbard MK, James K, Riach P, Dorey F. Collagenase versus placebo in the treatment of Peyronie\u2019s disease: a double-blind study. J Urol. 1993;149(1):56\u20138.","journal-title":"J Urol"},{"issue":"1","key":"45_CR133","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/jsm.12731","volume":"12","author":"LA Levine","year":"2015","unstructured":"Levine LA, Cuzin B, Mark S, et al. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie\u2019s disease: a phase 3 open-label study. J Sex Med. 2015;12(1):248\u201358.","journal-title":"J Sex Med"},{"issue":"9","key":"45_CR134","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/j.1464-410X.2010.09331.x","volume":"106","author":"S Chitale","year":"2010","unstructured":"Chitale S, Morsey M, Swift L, Sethia K. Limited shock wave therapy vs sham treatment in men with Peyronie\u2019s disease: results of a prospective randomized controlled double-blind trial. BJU Int. 2010;106(9):1352\u20136.","journal-title":"BJU Int"},{"issue":"11","key":"45_CR135","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1111\/jsm.12275","volume":"10","author":"G Hatzichristodoulou","year":"2013","unstructured":"Hatzichristodoulou G, Meisner C, Gschwend JE, Stenzl A, Lahme S. Extracorporeal shock wave therapy in Peyronie\u2019s disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med. 2013;10(11):2815\u201321.","journal-title":"J Sex Med"},{"issue":"2","key":"45_CR136","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.eururo.2009.05.012","volume":"56","author":"A Palmieri","year":"2009","unstructured":"Palmieri A, Imbimbo C, Longo N, et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie\u2019s disease. Eur Urol. 2009;56(2):363\u20139.","journal-title":"Eur Urol"},{"issue":"2","key":"45_CR137","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1365-2605.2011.01226.x","volume":"35","author":"A Palmieri","year":"2012","unstructured":"Palmieri A, Imbimbo C, Creta M, Verze P, Fusco F, Mirone V. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie\u2019s disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl. 2012;35(2):190\u20135.","journal-title":"Int J Androl"},{"issue":"2","key":"45_CR138","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1743-6109.2008.01108.x","volume":"6","author":"P Gontero","year":"2009","unstructured":"Gontero P, Di Marco M, Giubilei G, et al. Use of penile extender device in the treatment of penile curvature as a result of Peyronie\u2019s disease. Results of a phase II prospective study. J Sex Med. 2009;6(2):558\u201366.","journal-title":"J Sex Med"},{"issue":"6","key":"45_CR139","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/j.1743-6109.2008.00814.x","volume":"5","author":"LA Levine","year":"2008","unstructured":"Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie\u2019s disease: a single-center pilot study. J Sex Med. 2008;5(6):1468\u201373.","journal-title":"J Sex Med"},{"issue":"8","key":"45_CR140","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/j.1464-410X.2010.09365.x","volume":"106","author":"AA Raheem","year":"2010","unstructured":"Raheem AA, Garaffa G, Raheem TA, et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie\u2019s disease. BJU Int. 2010;106(8):1178\u201380.","journal-title":"BJU Int"},{"issue":"4","key":"45_CR141","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0022-5347(01)61613-6","volume":"161","author":"TF Lue","year":"1999","unstructured":"Lue TF, El-Sakka AI. Lengthening shortened penis caused by Peyronie\u2019s disease using circular venous grafting and daily stretching with a vacuum erection device. J Urol. 1999;161(4):1141\u20134.","journal-title":"J Urol"},{"issue":"5 Pt 2","key":"45_CR142","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/S0022-5347(17)36378-4","volume":"149","author":"JH Kim","year":"1993","unstructured":"Kim JH, Carson 3rd CC. Development of Peyronie\u2019s disease with the use of a vacuum constriction device. J Urol. 1993;149(5 Pt 2):1314\u20135.","journal-title":"J Urol"},{"issue":"2","key":"45_CR143","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0022-5347(01)66442-5","volume":"155","author":"LS Hakim","year":"1996","unstructured":"Hakim LS, Munarriz RM, Kulaksizoglu H, Nehra A, Udelson D, Goldstein I. Vacuum erection associated impotence and Peyronie\u2019s disease. J Urol. 1996;155(2):534\u20135.","journal-title":"J Urol"},{"issue":"1","key":"45_CR144","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0022-5347(17)66945-3","volume":"114","author":"WL Furlow","year":"1975","unstructured":"Furlow WL, Swenson Jr HE, Lee RE. Peyronie\u2019s disease: a study of its natural history and treatment with orthovoltage radiotherapy. J Urol. 1975;114(1):69\u201371.","journal-title":"J Urol"},{"issue":"6","key":"45_CR145","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0090-4295(00)00805-0","volume":"56","author":"L Incrocci","year":"2000","unstructured":"Incrocci L, Hop WC, Slob AK. Current sexual functioning in 106 patients with Peyronie\u2019s disease treated with radiotherapy 9\u00a0years earlier. Urology. 2000;56(6):1030\u20134.","journal-title":"Urology"},{"issue":"1","key":"45_CR146","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ijrobp.2005.06.009","volume":"64","author":"M Niewald","year":"2006","unstructured":"Niewald M, Wenzlawowicz KV, Fleckenstein J, Wisser L, Derouet H, Rube C. Results of radiotherapy for Peyronie\u2019s disease. Int J Radiat Oncol Biol Phys. 2006;64(1):258\u201362.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"45_CR147","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.urology.2011.12.036","volume":"79","author":"M Adibi","year":"2012","unstructured":"Adibi M, Hudak SJ, Morey AF. Penile plication without degloving enables effective correction of complex Peyronie\u2019s deformities. Urology. 2012;79(4):831\u20135.","journal-title":"Urology"},{"issue":"9","key":"45_CR148","first-page":"2221","volume":"5","author":"FL Taylor","year":"2008","unstructured":"Taylor FL, Levine LA. Surgical correction of Peyronie\u2019s disease via tunica albuginea plication or partial plaque excision with pericardial graft: long-term follow up. J SexMed. 2008;5(9):2221\u20138. discussion 2229\u20132230.","journal-title":"J SexMed"},{"issue":"2","key":"45_CR149","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eururo.2007.04.045","volume":"53","author":"A Kadioglu","year":"2008","unstructured":"Kadioglu A, Sanli O, Akman T, Cakan M, Erol B, Mamadov F. Surgical treatment of Peyronie\u2019s disease: a single center experience with 145 patients. Eur Urol. 2008;53(2):432\u20139.","journal-title":"Eur Urol"},{"issue":"5","key":"45_CR150","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/j.1743-6109.2007.00453.x","volume":"4","author":"JR Kovac","year":"2007","unstructured":"Kovac JR, Brock GB. Surgical outcomes and patient satisfaction after dermal, pericardial, and small intestinal submucosal grafting for Peyronie\u2019s disease. J Sex Med. 2007;4(5):1500\u20138. Describes use of various grafts in plaque incision\/excision for PD and reports outcomes.","journal-title":"J Sex Med"},{"issue":"3","key":"45_CR151","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1743-6109.04046.x","volume":"1","author":"J Mulhall","year":"2004","unstructured":"Mulhall J, Ahmed A, Anderson M. Penile prosthetic surgery for Peyronie\u2019s disease: defining the need for intraoperative adjuvant maneuvers. J Sex Med. 2004;1(3):318\u201321. Describes IPP placement for the surgical management in the PD patient with ED unresponsive to medical therapy and describes how to decide whether adjuvant maneuvers are necessary, as well as how to perform them.","journal-title":"J Sex Med"},{"issue":"1","key":"45_CR152","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0090-4295(03)00244-9","volume":"62","author":"MF Usta","year":"2003","unstructured":"Usta MF, Bivalacqua TJ, Sanabria J, Koksal IT, Moparty K, Hellstrom WJ. Patient and partner satisfaction and long-term results after surgical treatment for Peyronie\u2019s disease. Urology. 2003;62(1):105\u20139.","journal-title":"Urology"},{"issue":"4","key":"45_CR153","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0022-5347(17)38447-1","volume":"145","author":"MK Gelbard","year":"1991","unstructured":"Gelbard MK, Hayden B. Expanding contractures of the tunica albuginea due to Peyronie\u2019s disease with temporalis fascia free grafts. J Urol. 1991;145(4):772\u20136.","journal-title":"J Urol"},{"issue":"6","key":"45_CR154","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.eururo.2008.11.041","volume":"55","author":"L Cormio","year":"2009","unstructured":"Cormio L, Zucchi A, Lorusso F, et al. Surgical treatment of Peyronie\u2019s disease by plaque incision and grafting with buccal mucosa. Eur Urol. 2009;55(6):1469\u201375.","journal-title":"Eur Urol"},{"issue":"5","key":"45_CR155","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1159\/000049831","volume":"40","author":"E Akkus","year":"2001","unstructured":"Akkus E, Ozkara H, Alici B, et al. Incision and venous patch graft in the surgical treatment of penile curvature in Peyronie\u2019s disease. Eur Urol. 2001;40(5):531\u20136. discussion 537.","journal-title":"Eur Urol"},{"issue":"4","key":"45_CR156","first-page":"491","volume":"16","author":"FA Yafi","year":"2015","unstructured":"Yafi FA, Sangkum P, McCaslin IR, Hellstrom WJ. Strategies for penile prosthesis placement in Peyronie\u2019s disease and corporal fibrosis. Curr Urol Rep. 2015;16(4):491.","journal-title":"Curr Urol Rep"},{"issue":"6","key":"45_CR157","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/jsm.12530","volume":"11","author":"PH Chung","year":"2014","unstructured":"Chung PH, Scott JF, Morey AF. High patient satisfaction of inflatable penile prosthesis insertion with synchronous penile plication for erectile dysfunction and Peyronie\u2019s disease. J Sex Med. 2014;11(6):1593\u20138.","journal-title":"J Sex Med"},{"issue":"2","key":"45_CR158","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1439-0272.2012.01318.x","volume":"45","author":"T Akman","year":"2013","unstructured":"Akman T, Tefekli A, Armagan A, et al. Decorin as a new treatment alternative in Peyronie\u2019s disease: preliminary results in the rat model. Andrologia. 2013;45(2):101\u20136.","journal-title":"Andrologia"},{"issue":"3","key":"45_CR159","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.eururo.2012.09.034","volume":"63","author":"F Castiglione","year":"2013","unstructured":"Castiglione F, Hedlund P, Van der Aa F, et al. Intratunical injection of human adipose tissue-derived stem cells prevents fibrosis and is associated with improved erectile function in a rat model of Peyronie\u2019s disease. Eur Urol. 2013;63(3):551\u201360.","journal-title":"Eur Urol"},{"issue":"2","key":"45_CR160","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.2047-2927.2013.00181.x","volume":"2","author":"A Gokce","year":"2014","unstructured":"Gokce A, Abd Elmageed ZY, Lasker GF, et al. Adipose tissue-derived stem cell therapy for prevention and treatment of erectile dysfunction in a rat model of Peyronie\u2019s disease. Andrology. 2014;2(2):244\u201351.","journal-title":"Andrology"}],"container-title":["Current Sexual Health Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11930-015-0045-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11930-015-0045-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11930-015-0045-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T11:14:13Z","timestamp":1717845253000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11930-015-0045-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,15]]},"references-count":160,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["45"],"URL":"https:\/\/doi.org\/10.1007\/s11930-015-0045-y","relation":{},"ISSN":["1548-3584","1548-3592"],"issn-type":[{"value":"1548-3584","type":"print"},{"value":"1548-3592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,15]]}}}